Two citizen petitions ask the FDA to add a black box warning to the popular restless legs syndrome drugs. By Dillon Stickle In 2004, neurologist Daniel Lee, MD, was one of the investigators who declared ropinirole a well-tolerated and effective treatment for restless legs syndrome (RLS), contributing to the US Food and Drug Administration’s (FDA) approval … Continue reading Long-time RLS Researchers: Dopamine Agonists May Cause Psychiatric Adverse Events, Even at Comparatively Low Doses